US EditionTRANSFORM II study of sirolimus DCB completes patient enrolment - Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
TRANSFORM II Study of Concept Medical’s MagicTouch SCB Completes Enrollment - Cardiac Interventions Today
June 16, 2025—Concept Medical Inc. recently announced the completion of enrollment in the TRANSFORM II randomized controlled trial (RCT). The study is evaluating the safety and efficacy of the company’s MagicTouch sirolimus-coated balloon (SCB) compared to an everolimus-eluting stent in treating de novo lesions in coronary vessels. The company stated that the study has achieved its target enrollment of > 1,820 patients, with a total of 1,832 pat…
TRANSFORM II study of sirolimus DCB completes patient enrolment - Cardiovascular News
Enrolment has been completed in the TRANSFORM II randomised controlled trial, comparing the MagicTouch (Concept Medical) sirolimus drug-coated balloon (DCB) to an everolimus drug-eluting stent (DES) in treating de-novo coronary lesions. TRANSFORM II is an investigator-initiated trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare (RIC) in Milan, Italy, taking place in 52 centres across Europe, Asia and South America. A total of 1,…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
